Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren's syndrome.
Anti-SSA
Central nervous system
Complement C3
Glucocorticoids
Sjögren’s syndrome
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
27
06
2022
accepted:
10
11
2022
revised:
05
11
2022
pubmed:
19
11
2022
medline:
27
1
2023
entrez:
18
11
2022
Statut:
ppublish
Résumé
Evidence for central nervous system involvement in primary Sjögren's syndrome (pSS) patients is controversial and extremely limited. We aimed to describe the clinical profiles and high-risk indicators of primary Sjögren's syndrome (pSS) patients with central nervous system (CNS) involvement (pSS-CNS). A total of 412 participants with pSS from a hospital in China from January 2012 to December 2019 were enrolled in the retrospective study. 42 pSS-CNS patients were compared with 370 pSS patients without CNS involvement. The clinical features, laboratory examinations, imaging characteristics, and treatment of the pSS-CNS cases were systematically analyzed. Potential risk factors related to pSS-CNS patients were identified by multivariate logistic regression analysis. The prevalence of central nervous system involvement in the studied pSS patients was 10.2% (42/412), with 31.3% (14/42) of pSS patients having neurological manifestations as the initial symptom. The manifestations of hemiparesis (35.7%, 15/42), paraparesis (28.6%, 12/42), dysphonia (31.0%, 13/42), blurred vision (21.4%, 9/42), and dysfunctional proprioception (23.8%, 10/42) were more common in the pSS-CNS patients. Cerebral infarction (57.1%, 24/42), demyelination (31.0%, 13/42), myelitis (23.8%, 11/42), and angiostenosis (21.4%, 9/42) were most often found on MRI or CT scan imaging in the pSS-CNS patients. Intrathecal IgG level and total protein of cerebrospinal fluid were increased in 50% (8/16) of the pSS-CNS group. In comparison with patients without CNS involvement, the pSS-CNS patients were found to also have kidney and lung involvement, hematologic abnormalities, positive ANA and anti-SSA antibody tests, and reduced complement 3 (C3) and complement 4 (C4) levels (all p < 0.05). The prevalence of lung involvement, immune thrombocytopenia, and high-titer ANA (1:1000) were significantly higher in pSS-CNS disease activity compared to those in the moderately active group. Multivariate analysis identified lung involvement, anti-SSA positivity, and low C3 levels as prognostic factors for pSS-CNS. After high-dose glucocorticoids and immunosuppressive therapy, 60.5% (26/38) of pSS-CNS patients improved, 36.8% (14/38) were unresponsive to treatment, and 2.6% (1/38) died. Clinical features are diverse in pSS-CNS patients, and the morbidity rate is low. CNS involvement was the initial presentation in state percentage here pSS patients. Pulmonary involvement, a positive anti-SSA antibody test, and reduced C3 levels are potential risk factors for CNS involvement in pSS. Treatment with high-dose glucocorticoids and immunosuppressive therapy appeared effective in 60% of pSS-CNS patients. Key Points • The CNS manifestations of pSS are diverse, and CNS imaging and CSF analysis are important for the diagnosis. • Pulmonary involvement, positive anti-SSA, and reduced C3 levels are potential risk factors of pSS-CNS. • About 60% of pSS-CNS patients were responsive to high-dose glucocorticoid administration and immunosuppressive therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence for central nervous system involvement in primary Sjögren's syndrome (pSS) patients is controversial and extremely limited. We aimed to describe the clinical profiles and high-risk indicators of primary Sjögren's syndrome (pSS) patients with central nervous system (CNS) involvement (pSS-CNS).
METHODS
METHODS
A total of 412 participants with pSS from a hospital in China from January 2012 to December 2019 were enrolled in the retrospective study. 42 pSS-CNS patients were compared with 370 pSS patients without CNS involvement. The clinical features, laboratory examinations, imaging characteristics, and treatment of the pSS-CNS cases were systematically analyzed. Potential risk factors related to pSS-CNS patients were identified by multivariate logistic regression analysis.
RESULTS
RESULTS
The prevalence of central nervous system involvement in the studied pSS patients was 10.2% (42/412), with 31.3% (14/42) of pSS patients having neurological manifestations as the initial symptom. The manifestations of hemiparesis (35.7%, 15/42), paraparesis (28.6%, 12/42), dysphonia (31.0%, 13/42), blurred vision (21.4%, 9/42), and dysfunctional proprioception (23.8%, 10/42) were more common in the pSS-CNS patients. Cerebral infarction (57.1%, 24/42), demyelination (31.0%, 13/42), myelitis (23.8%, 11/42), and angiostenosis (21.4%, 9/42) were most often found on MRI or CT scan imaging in the pSS-CNS patients. Intrathecal IgG level and total protein of cerebrospinal fluid were increased in 50% (8/16) of the pSS-CNS group. In comparison with patients without CNS involvement, the pSS-CNS patients were found to also have kidney and lung involvement, hematologic abnormalities, positive ANA and anti-SSA antibody tests, and reduced complement 3 (C3) and complement 4 (C4) levels (all p < 0.05). The prevalence of lung involvement, immune thrombocytopenia, and high-titer ANA (1:1000) were significantly higher in pSS-CNS disease activity compared to those in the moderately active group. Multivariate analysis identified lung involvement, anti-SSA positivity, and low C3 levels as prognostic factors for pSS-CNS. After high-dose glucocorticoids and immunosuppressive therapy, 60.5% (26/38) of pSS-CNS patients improved, 36.8% (14/38) were unresponsive to treatment, and 2.6% (1/38) died.
CONCLUSION
CONCLUSIONS
Clinical features are diverse in pSS-CNS patients, and the morbidity rate is low. CNS involvement was the initial presentation in state percentage here pSS patients. Pulmonary involvement, a positive anti-SSA antibody test, and reduced C3 levels are potential risk factors for CNS involvement in pSS. Treatment with high-dose glucocorticoids and immunosuppressive therapy appeared effective in 60% of pSS-CNS patients. Key Points • The CNS manifestations of pSS are diverse, and CNS imaging and CSF analysis are important for the diagnosis. • Pulmonary involvement, positive anti-SSA, and reduced C3 levels are potential risk factors of pSS-CNS. • About 60% of pSS-CNS patients were responsive to high-dose glucocorticoid administration and immunosuppressive therapy.
Identifiants
pubmed: 36401063
doi: 10.1007/s10067-022-06448-w
pii: 10.1007/s10067-022-06448-w
pmc: PMC9873757
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-451Subventions
Organisme : Xiamen Science and Technology(Medical and Health )
ID : 3502Z20184061
Organisme : iamen Medical and Health Guidance Project
ID : 3502Z20199137
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : iamen Medical and Health Guidance Project
ID : 3502Z20179008
Organisme : Fujian Medical and Health Training Project for young and middle-aged backbone talents
ID : 2020GGB068
Organisme : National Defense Science and Technology Innovation Fund of the Chinese Academy of Sciences
ID : 81901669
Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
Mariette X, Criswell LA (2018) Primary Sjögren’s syndrome[J]. N Engl J Med 378(10):931–939
doi: 10.1056/NEJMcp1702514
pubmed: 29514034
Cafaro G, Croia C, Argyropoulou OD et al (2019) One year in review 2019: Sjögren’s syndrome[J]. Clin Exp Rheumatol 37 Suppl 118(3):3–15
pubmed: 31464675
Baldini C, Pepe P, Quartuccio L et al (2014) Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients[J]. Rheumatology (Oxford) 53(5):839–844
doi: 10.1093/rheumatology/ket427
pubmed: 24369420
Patel R, Shahane A (2014) The epidemiology of Sjögren’s syndrome[J]. Clin Epidemiol 6:247–255
pubmed: 25114590
pmcid: 4122257
Carvajal Alegria G, Guellec D, Mariette X et al (2016) Epidemiology of neurological manifestations in Sjögren’s syndrome: data from the French ASSESS Cohort[J]. RMD Open 2(1):e000179
doi: 10.1136/rmdopen-2015-000179
pubmed: 27110384
pmcid: 4838763
Jaskólska M, Chylińska M, Masiak A et al (2020) Neuro-Sjögren: uncommon or underestimated problem?[J]. Brain Behav 10(8):e01665
doi: 10.1002/brb3.1665
pubmed: 32583978
pmcid: 7428478
Yuan J, Gong L, Wu H et al (2018) Case report of primary Sjögren Syndrome with simple trigeminal lesion as initial symptom[J]. J Neuroimmunol 324:126–128
doi: 10.1016/j.jneuroim.2018.08.005
pubmed: 30170790
Segal B, Carpenter A, Walk D (2008) Involvement of nervous system pathways in primary Sjögren’s syndrome[J]. Rheum Dis Clin North Am 34(4):885–906, viii
doi: 10.1016/j.rdc.2008.08.001
pubmed: 18984410
Mccoy SS, Baer AN (2017) Neurological complications of Sjögren’s syndrome: diagnosis and management[J]. Curr Treatm Opt Rheumatol 3(4):275–288
doi: 10.1007/s40674-017-0076-9
pubmed: 30627507
pmcid: 6322693
Massara A, Bonazza S, Castellino G et al (2010) Central nervous system involvement in Sjögren’s syndrome: unusual, but not unremarkable–clinical, serological characteristics and outcomes in a large cohort of Italian patients[J]. Rheumatology (Oxford) 49(8):1540–1549
doi: 10.1093/rheumatology/keq111
pubmed: 20444860
Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis 61(6):554–558
doi: 10.1136/ard.61.6.554
pubmed: 12006334
pmcid: 1754137
Seror R, Ravaud P, Mariette X et al (2011) EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome[J]. Ann Rheum Dis 70(6):968–972
doi: 10.1136/ard.2010.143743
pubmed: 21345815
Xing H, Pang H, Du T et al (2021) Establishing a risk prediction model for atherosclerosis in systemic lupus erythematosus[J]. Front Immunol 12:622216
doi: 10.3389/fimmu.2021.622216
pubmed: 33936038
pmcid: 8085548
Fan G, Dai F, Chen S et al (2021) Neurological involvement in patients with primary Sjögren’s syndrome[J]. J Clin Rheumatol 27(2):50–55
doi: 10.1097/RHU.0000000000001128
pubmed: 33617165
Teixeira F, Moreira I, Silva AM et al (2013) Neurological involvement in primary Sjögren syndrome[J]. Acta Reumatol Port 38(1):29–36
pubmed: 24131909
Morreale M, Marchione P, Giacomini P et al (2014) Neurological involvement in primary Sjögren syndrome: a focus on central nervous system[J]. PLoS ONE 9(1):e84605
doi: 10.1371/journal.pone.0084605
pubmed: 24465419
pmcid: 3896357
Moreira I, Teixeira F, Martins Silva A et al (2015) Frequent involvement of central nervous system in primary Sjögren syndrome[J]. Rheumatol Int 35(2):289–294
doi: 10.1007/s00296-014-3097-9
pubmed: 25056402
Jamilloux Y, Magy L, Hurtevent JF et al (2014) Immunological profiles determine neurological involvement in Sjögren’s syndrome[J]. Eur J Intern Med 25(2):177–181
doi: 10.1016/j.ejim.2013.10.005
pubmed: 24176941
Flores-Chávez A, Kostov B, Solans R et al (2018) Severe, life-threatening phenotype of primary Sjögren’s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry)[J]. Clin Exp Rheumatol 36 Suppl 112(3):121–129
pubmed: 30156546
Delalande S, De Seze J, Fauchais AL et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients[J]. Medicine (Baltimore) 83(5):280–291
doi: 10.1097/01.md.0000141099.53742.16
pubmed: 15342972
Ramos-Casals M, Brito-Zerón P, Solans R et al (2014) Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)[J]. Rheumatology (Oxford) 53(2):321–331
doi: 10.1093/rheumatology/ket349
pubmed: 24162151
Seror R, Theander E, Brun JG et al (2015) Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)[J]. Ann Rheum Dis 74(5):859–866
doi: 10.1136/annrheumdis-2013-204615
pubmed: 24442883
Seror R, Bootsma H, Saraux A et al (2016) Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)[J]. Ann Rheum Dis 75(2):382–389
doi: 10.1136/annrheumdis-2014-206008
pubmed: 25480887
Chivasso C, Sarrand J, Perret J et al (2021) The involvement of innate and adaptive immunity in the initiation and perpetuation of Sjögren’s syndrome[J]. Int J Mol Sci 22(2):658
doi: 10.3390/ijms22020658
pubmed: 33440862
pmcid: 7826728
Cornec D, Jamin C, Pers JO (2014) Sjögren’s syndrome: where do we stand, and where shall we go?[J]. J Autoimmun 51:109–114
doi: 10.1016/j.jaut.2014.02.006
pubmed: 24612946
Alexander EL, Ranzenbach MR, Kumar AJ et al (1994) Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjögren’s syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates[J]. Neurology 44(5):899–908
doi: 10.1212/WNL.44.5.899
pubmed: 8190294
Ye W, Chen S, Huang X et al (2018) Clinical features and risk factors of neurological involvement in Sjögren’s syndrome[J]. BMC Neurosci 19(1):26
doi: 10.1186/s12868-018-0427-y
pubmed: 29703151
pmcid: 5924492
Gono T, Kawaguchi Y, Katsumata Y et al (2011) Clinical manifestations of neurological involvement in primary Sjögren’s syndrome[J]. Clin Rheumatol 30(4):485–490
doi: 10.1007/s10067-010-1458-7
pubmed: 20393864
Zhao J, Chen Q, Zhu Y et al (2020) Nephrological disorders and neurological involvement in pediatric primary Sjogren syndrome:a case report and review of literature[J]. Pediatr Rheumatol Online J 18(1):39
doi: 10.1186/s12969-020-00431-y
pubmed: 32448292
pmcid: 7245745
Alexander EL, Provost TT, Sanders ME et al (1988) Serum complement activation in central nervous system disease in Sjögren’s syndrome[J]. Am J Med 85(4):513–518
doi: 10.1016/S0002-9343(88)80087-1
pubmed: 3177398
Brito-Zerón P, Acar-Denizli N, Ng WF et al (2018) How immunological profile drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project)[J]. Clin Exp Rheumatol 36 Suppl 112(3):102–112
pubmed: 30156539
Kahlenberg JM (2011) Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjögren’s syndrome[J]. Semin Arthritis Rheum 40(4):343–348
doi: 10.1016/j.semarthrit.2010.05.005
pubmed: 20655576
Akaishi T, Takahashi T, Fujihara K et al (2021) Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders[J]. J Neurol 268(5):1938–1944
doi: 10.1007/s00415-020-10377-6
pubmed: 33416998
Pars K, Pul R, Schwenkenbecher P et al (2017) Cerebrospinal fluid findings in neurological diseases associated with Sjögren’s syndrome[J]. Eur Neurol 77(1–2):91–102
doi: 10.1159/000454765
pubmed: 27997917
Perzyńska-Mazan J, Maślińska M, Gasik R (2018) Neurological manifestations of primary Sjögren’s syndrome[J]. Reumatologia 56(2):99–105
doi: 10.5114/reum.2018.75521
pubmed: 29853725
pmcid: 5974632
Alexander EL, Lijewski JE, Jerdan MS et al (1986) Evidence of an immunopathogenic basis for central nervous system disease in primary Sjögren’s syndrome[J]. Arthritis Rheum 29(10):1223–1231
doi: 10.1002/art.1780291007
pubmed: 2429673
Tjensvoll AB, Lauvsnes MB, Zetterberg H et al (2021) Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren’s syndrome[J]. J Neurol 268(4):1385–1394
doi: 10.1007/s00415-020-10290-y
pubmed: 33128084
Sève P, Gachon E, Petiot P et al (2007) Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren’s syndrome[J]. Rheumatol Int 28(2):175–177
doi: 10.1007/s00296-007-0396-4
pubmed: 17641898
Beh SC, Kildebeck E, Narayan R et al (2017) High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes[J]. J Neurol Sci 372:187–195
doi: 10.1016/j.jns.2016.11.012
pubmed: 28017209
Soliotis FC, Mavragani CP, Moutsopoulos HM (2004) Central nervous system involvement in Sjogren’s syndrome[J]. Ann Rheum Dis 63(6):616–620
doi: 10.1136/ard.2003.019497
pubmed: 15140765
pmcid: 1755013